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Abstract
The FMR1 gene, mapping to an area of the X chromosome closely associated with autoimmunity also affects ovarian
reserve, with specific genotypes associated with distinct ovarian aging patterns. They, therefore, could also be associated
with differences of in vitro fertilization (IVF) outcomes, reported between races/ethnicities. We analyzed 339 consecutive IVF
patients, 232 Caucasian, 59 African and 48 Asian, for FMR1 genotypes, and tested by multiple logistic regressions for
associations between race/ethnicity, FMR1 genotype, autoimmunity and pregnancy chances with IVF. FMR1 genotypes were
predictive of pregnancy (P=0.046), het-norm/low most significantly and with decreasing chance in comparison to norm
genotypes (OR 0.44; 95% CI 0.23–0.85; P=0.014). Race/ethnicity was, overall, independently associated (P=0.03), African
demonstrating decreased odds in comparison to Caucasian (OR 0.33. 95%CI 0.13–0.79; P=0.014). Autoimmunity did not
differ but interaction of autoimmunity with FMR1 genotype almost reached significance (P=0.07). Logistic regression with
race/ethnicity and interaction between FMR1 genotype and autoimmunity in the model, demonstrated 2.5-times the odds
of being associated with autoimmune positivity (OR 2.5, 1.34–4.55; P=0.004). FMR1 genotypes offer a possible explanation
for differences in IVF outcomes between races/ethnicities.
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Introduction
Infertility treatment outcomes vary in different races/ethnic-
ities [1–9], and disparities increase with improving outcomes
[10]. This does not surprise: For example, primary ovarian
insufficiency (POI, also called premature ovarian failure, POF)
varies [11], menopause differs [12] and Chinese oocytes donors
demonstrate more premature ovarian aging (POA, also called
occult primary ovarian insufficiency, OPOI) than Caucasians
[13] and higher estradiol levels [9]. Asians also present with
milder polycystic ovary (PCO) phenotype than Caucasians and
Africans [14], and African women in general experience
excessive infertility [15]. Two studies demonstrated IVF cycle
differences, though no difference in pregnancy rates/live births
[9,16]. Why outcome differences with intrauterine inseminations
[5] or in vitro fertilization (IVF) [3,4,6–9] are observed, is
unknown.
Distribution of fragile X mental retardation (FMR1) genotypes
varies between Caucasian, African and Asian women [17]. The
gene maps to the 59 untranslated exon 1 on the X chromosome
(Xq27.3) [18], and is primarily assessed in women attempting
conception. Genotype classes, defined by length of polymorphic
expansions of CGG nucleotides, denote increased risk towards
mostly neuro-psychiatric conditions [19]. FMR1 is one amongst a
number of genes generating diseases via trinucleotide repeat
expansions. Others are, for example, myotonic dystrophy and
Huntington’s disease [20].
At so-called premutation range genotype (American College of
Medical Genetics, 55 to approximately 200 CGGs), and full
mutation (above approximately 200–230), FMR1 induces severe
neuro-psychiatric conditions [in male premutation carriers fragile
X – associated tremor/ataxia syndrome (FXTAS) a neurodegen-
erative disease]. Full mutations (fragile X syndrome) are the most
frequent known genetic cause of autism and mental retardation in
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and/or more mildly affected than males [19].
Women with premutations express the only non-neuro-psychi-
atric condition associated with polymorphic CGG expansions,
POI/POF) [19], offering until recently the only hint of an ovary-
related function of FMR1.
In elucidating some of this function, we newly defined
genotypes, based on entirely different CGG count ranges than
those defining neuro-psychiatric risks. Based on a normal range of
26 to 34 (median 30) CGG repeats [21], consistent amongst all
races [17], those genotypes determine different ovarian aging
patterns and, therefore, variable declines in ovarian reserve [21].
At approximately the median of this normal range lies the
distribution peak (29–30 CGG repeats), reported by Fu and
associates in the general population [22]. Exactly at median (30
CGG repeats) lies the switching point between positive and
negative message and point of maximal translation of the gene
product (fragile X mental retardation protein, FMRP), reported by
Chen et al. [23].
CGG counts on the two X chromosome alleles define whether a
genotype is normal (norm), heterozygous (het) or homozygous (hom).
Norm women demonstrate distinctively different ovarian aging
from het and hom genotypes [21]. Since ovarian reserve at all ages
greatly affects treatment success of infertile patients [24], FMR1
genotypes should, therefore, demonstrate significant impact on
treatment outcomes.
Whether race/ethnicity affects impacts of FMR1 genotypes on
IVF is unknown. How FMR1 effects differ between races/
ethnicities was recently suggested a desirable study subject [25].
FMR1 genotype differences could represent possible explanations
for observed differences in infertility treatment outcomes.
Methods
Patients
We investigated 339 consecutive infertility patients, who have
been subject of a prior report [26]. Their characteristics are
summarized in Table 1: Mean age was 3865 years; mean BMI
2465; mean AMH at time of presentation was 1.461.7 ng/mL;
mean baseline follicle stimulating hormone (FSH) 11.066.4 mIU/
mL; mean estradiol was 53.1639.9 ng/mL.
Patients self-identified in race/ethnicity (or were excluded) as
Caucasian (European descendancies but also including Hispanics
self-identified as Caucasians); African (black women of African,
Caribbean, Hispanic and Afro-American descent); and Asian
(mostly Chinese, minorities with Indian or Pakistani heritage and
rarely from other Asian countries); Hispanics mostly self-identified
with other ethnic groups. Middle-Eastern (of Arab, Druze and
Iranian) and Jewish (Ashkenazi and Sephardic) patients were
included with Caucasians.
Laboratory investigations
FMR1 genotypes were designated based on a normal range of
26–34 (median 30) CGGs [21] and as previously utilized in
defining specific patient populations [26]: norm was defined by
both alleles within range, het by one allele outside and norm/low or
norm/high, depending on the abnormal count allele being above or
below normal range. Both alleles outside range defined hom. As hom
patients represented only 1–2 percent in all groups, statistical
analysis was impossible, and they were excluded.
FMR1 analyses utilized routine clinical assay systems [21].
Hormone assays were performed in house [21].
Patients were defined as either non-immune or autoimmune
based on a previously reported laboratory screen, and considered
autoimmune with any one positive test [26–28]. This definition
consciously selects sensitivity over specificity and biases against
findings of statistical associations with presence of autoimmunity.
This panel, however, previously has been demonstrated to define
risk towards premature ovarian senescence [27,28] and associa-
tions between FMR1 sub-genotypes, a slim PCO-like phenotype
and autoimmunity [26].
In vitro fertilization (IVF) outcomes
IVF data were extracted from the center’s confidential
electronic data base. Data in question resulted in manual chart
review.
Statistical analysis
Data are shown as mean 6 SD or as raw numbers and
percentages. Demographic and biochemical data were analyzed
with one way analysis of variance or with chi square. When an
analysis of variance was significant, Student Neuman Keuls (SNK)
test was used to analyze differences between group means.
Differences between groups in proportions of pregnancies
established with IVF were analyzed with univariate logistic
regression, and were considered significant at P,0.05.
Multivariate logistic regression models of clinical pregnancy
after IVF were then used for covariates, such as age and different
ovarian reserve parameters, and to examine separate and
combined effects of FMR1 genotypes and race/ethnicity.
Institutional Review Board
All data utilized in this study were extracted from medical
records and/or the center’s confidential electronic research data
base. Patients, at initial consultation, routinely sign an informed
consent, which allows members of the center to use their medical
records for research purposes as long as their identity is protected
and all medical information remains confidential. These condi-
tions were met for this study and the study, therefore, qualified for
expedited review by the center’s Institutional Review Board.
Table 1. Patient characteristics.
Caucasian African Asian Total
n=232 n=59 n=48 n=339
Age (years) 38653 8 653 8 653 8 65
BMI 2465
1,2 2666
1,3 2263
2,3 2465
AMH (ng/mL) 1.361.6 2.261.3 1.461.3 1.461.7
FSH (mIU/mL) 11.066.5 11.867.5 10.264.8 11.066.4
Estradiol (ng/mL) 55.7646.8 50.3617.5 44.4617.9 53.1639.9
IVF Parameters
Oocytes 8677 677 668 67
Embryos 2612 612 612 61
Cancelled cycles (%) 10 (4.3) 3 (5.1) 4 (8.3) 17 (5.0)
Pregnancies (%) 60 (25.9)
4 6 (10.2)
4,5 14 (29.2)
5 80 (23.6)
FMR1 Genotypes (%)
norm 127 (54.7) 31 (52.5) 25 (52.1) 183 (54.0)
het-norm/high 39 (16.8) 9 (15.3) 14 (29.2) 62 (18.3)
het-norm/low 66 (28.4) 19 (32.2) 9 (18.8) 94 (27.7)
Differences between racial/ethnic groups were not significant except for where
noted with P values:
1=0.001;
2 =0.03;
3,0.0001;
4, 5 ,0.05.
doi:10.1371/journal.pone.0018781.t001
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The study group of 339 divided into 232 Caucasian, 59 African
and 48 Asian women. Table 1 summarizes patient characteristics.
Mean age was 3865 years and races/ethnicities did not vary.
Mean BMI was 2465 but Asians had the significantly lowest
(2263; p,0.0001 vs African, p=0.03 vs. Caucasian), followed by
Caucasians (2465; vs. African p=0.01) and Africans (2666).
AMH, FSH and estradiol did not differ.
Numbers of oocytes, transferred embryos and cycle cancella-
tions also did not differ. In univariate analysis clinical pregnancy
rates were, however, in Africans significantly lower than in
Caucasians and Asians (both P,0.05). Correcting for cycle
cancellations, the difference in clinical pregnancy rates between
Africans and Caucasians/Asians was maintained (both P,0.05).
FMR1 genotypes also did not reach significant differences,
though Asians demonstrated a trend towards more frequent het-
norm/high and Africans towards het-norm/low (Table 1).
Logistic regression confirmed FMR1 genotypes overall as
predictive of pregnancy rate (P=0.046), with most significance
through het-norm/low (OR 0.44; 95% CI 0.23–0.85; P=0.014) in
comparison to norm. Het-norm/high did not differ from norm in
predicting odds of pregnancy (OR 0.73; 95% CI 0.37–1.45; N.S.).
Adjusting for age and BMI increased the overall significance of
FMR1 (P=0.03) and did not change significance of het-norm/low
(OR 0.42; 95% CI 0.21–0.83; P=0.013).
When race/ethnicity was investigated by logistic regression,
pregnancy rates differed significantly (P=0.03). African demon-
strated significantly reduced odds of pregnancy compared to
Caucasian (OR 0.33, 95% CI 0.13–0.79; P=0.014). Adjustment
for age did not change odds of pregnancy (P=0.03 for overall
race/ethnicity and OR 0.31, 95% CI 0.12–0.79; P=0.01 for
African in comparison to Caucasian). Adding BMI, overall
significance was also maintained (P=0.02) and African race/
ethnicity further improved the association (OR 0.27, 0.10–0.70;
P=0.007).
Including in logistic regression FMR1 genotype, age and BMI,
race/ethnicity remained significant (P=0.03), African continued
to have significantly decreased odds of pregnancy compared to
Caucasian (OR 0.27, 95% CI 0.10–0.72; P=0.009), and within
the FMR1 categories het-norm/low continued decreased odds of
pregnancy compared to normal (OR 0.44, 95% CI 0.22–0.89;
P=0.02). Further adjusting this model with the log of individual
AMH values (a representation of ovarian function) caused the
FMR1 factor to lose significance but did not significantly change
effects of race/ethnicity.
We previously reported that in this patient population
autoimmunity almost reached independent association in predict-
ing pregnancy (P=0.06) [26]. Figure 1 demonstrates the
prevalence of autoimmunity. Differences, overall, did not reach
significance. The upper panel (A), however, demonstrates
differences within racial/ethnic groups based on FMR1 genotype.
The lower panel (B) offers further clarifications when the same
data are shown stratified by race/ethnicity within each FMR1
genotype.
Autoimmunity was overall most frequent amongst African
women (n=25, 42.4%), followed by Caucasians (n=92, 39.7%)
and least among Asians (n=17, 35.4%). The interaction between
FMR1 genotype and autoimmunity almost reached significance
(P=0.07), suggesting different FMR1 effects in races/ethnicities.
Association of autoimmunity in het-norm/low was most pronounced
in Caucasians, followed by Africans and the least in Asians. Het-
norm/high reduces autoimmunity risk significantly in Caucasians
(P,0.05). A similar non-significant trend was observed for
Africans. A non-significant increased proportion of individuals
with autoimmunity was observed among Asians. Risk towards
autoimmunity in all three races/ethnicities appears least affected
with norm FMR1.
Logistic regression, with race/ethnicity and interaction between
FMR1 genotype and autoimmunity in the model, has 2.5-times the
odds of being associated with autoimmune positivity (OR 2.5,
1.34–4.55; P=0.004).
Discussion
Race/ethnicity affects treatment outcomes in infertility [1–9].
Minority populations, whether of African [1,4,7,10], Asian [1–
3,5–9] or Hispanic [7] descent, demonstrate lower pregnancy
success than Caucasians. Why, has remained unresolved.
Searching for explanations for lower pregnancy rates in Chinese
women, we reported more POA/OPOI in Chinese than
Caucasian oocyte donors [13]. At the same time CGG
trinucleotide repeats in high-normal and intermediate ranges were
associated with premature FSH elevations [29,30]. We observed
that 26–34 CGG repeats represent normal in regards to ovarian
function [21], while counts below and above denote risk towards
POA/OPOI [31].
Distributions of outliers differed among races/ethnicities, with
Asians being most, Caucasians least homogenous [17]. Africans
(and to lesser degree Caucasians) demonstrated a preponderance
for abnormally low and Asians for mostly abnormally high outliers
[17]. At that point we, however, were still unaware that newly
defined FMR1 genotypes would be associated with specific ovarian
aging patterns, as later demonstrated [21,26].
Since then, het-norm/low has been associated with a PCO-like
ovarian phenotype, rapidly depleting follicles (and ovarian reserve)
[32], significantly reduced pregnancy chances in IVF and high risk
towards autoimmunity (with PCO-like ovarian phenotype 84%
likelihood) [26,33]. In contrast, het-norm/high, also associated with
risk towards POA/OPOI, reflects lower risk towards poorer IVF
pregnancy chances, and, indeed, appears protective against
autoimmunity (10% likelihood) [26,33].
That African women demonstrate decreased IVF pregnancy
rates and decreases in pregnancy chance with het-norm/low is,
therefore, not surprising. These results concur with previously
reported observations: African women demonstrate a preponder-
ance of abnormally low count CGG outliers [17], corresponding
to het-norm/low. Likely missing significance due to small patient
numbers, they also demonstrated the highest prevalence of het-
norm/low (Table 1).
Adjusting for various covariates maintained significant associ-
ations for pregnancy outcomes. Further adjusting the model with
log of individual AMH values (representative of ovarian reserve)
caused the FMR1 factor, however, to lose significance, while
maintaining significance of race/ethnicity. This suggests that
FMR1 effects on pregnancy chances are mostly ovarian, while
effects of race/ethnicity are not, and, likely, systemic (i.e.,
implantation-related). Autoimmunity, of course, therefore comes
immediately to mind as potential culprit but remains to be proven.
Based on previously noted associations between het-norm/low,
autoimmunity and diminished IVF pregnancy chances [26,33], we
expected similar associations here. This study, however, suggests
that, at least in regards to autoimmunity, FMR1 gene effects vary
between races/ethnicities. Multiple regression of autoimmune
status against race/ethnicity and FMR1 genotype, and the
interaction of the latter two, reached almost significance
(p=0.07; data not shown). Moreover, logistic regression, with
race/ethnicity and interaction between FMR1 genotype and
Impact of FMR1 Genotypes and Race on IVF Outcomes
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18781Figure 1. Prevalence of autoimmunity based on race/ethnicity and FMR1 genotype. Autoimmunity, overall, did not differ amongst the
three races/ethnicities. Panel A, however demonstrates differences in prevalence of autoimmunity within races, while Panel B demonstrates the same
data stratified by FMR1 genotype. The interaction between race/ethnicity and FMR1 genotypes, overall, almost reached significance (P=0.07),
suggesting different FMR1 effects in the three races/ethnicities. Logistic regression, with race/ethnicity and interaction between FMR1 genotype and
autoimmunity in the model, has 2.5-times the odds of being associated with autoimmune positivity (OR 2.5, 1.34–4.55; P=0.004).
doi:10.1371/journal.pone.0018781.g001
Impact of FMR1 Genotypes and Race on IVF Outcomes
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18781autoimmunity in the model demonstrated 2.5-times the odds of
being associated with autoimmunity.
In a different way of assessing results (Figure IB), women with
norm genotype should in all races/ethnicities represent the
approximate average of autoimmune prevalence (all races/
ethnicities, indeed, demonstrate similar prevalence). As autoim-
munity amongst African women with het-norm/low sub-genotype is
similar and, therefore, likely approximately normal, Caucasians
actually demonstrate excessive autoimmunity with this sub-
genotype, and Asians an unusually low prevalence. Asians, indeed,
demonstrate the by far lowest prevalence.
As previously reported for women with PCO-like phenotypes
[26,33], het-norm/high here also appears protective against
autoimmunity. This protective effect, however, extends only to
Caucasian and African women and not to Asian patients, who
actually demonstrate the highest autoimmune prevalence with het-
norm/high.
We previously also reported that het-norm/low sub-genotype
practically halves pregnancy chances in comparison to norm FMR1
genotype, het-norm/high falling in-between [26,32]. Here presented
data, therefore, concur since Africans exhibited lowest pregnancy
rates and highest prevalence of sub-genotype het-norm/low, while
Asians, with lowest prevalence of this sub-genotype, demonstrate
highest pregnancy rates.
These observations support FMR1 contributions to pregnancy
outcome differences between races but do not yet allow us to
accurately quantify these effects. Indeed, additional association
studies on larger patient numbers will be required before FMR1
trinucleotide repeats will become a clinically useful tool in
accurately predicting odds of pregnancy in association with the
IVF process. Until such data become available, it appears prudent
to consider the FMR1 genotype of infertility patients. Changes in
treatment protocols would, however, appear inappropriate, except
in clinical trials, and with appropriate informed consents.
The high IVF pregnancy rate amongst Asians is surprising,
contradicts reports of inferior IVF outcomes in Asians [1–3,5–8]
and our center’s own earlier results a number of years ago in egg
donors [13]. It, however, correlates well with a recent paper by
Huddleston et al., which reported comparable pregnancy rates in
Asians and Caucasian egg donors but higher estradiol levels in
Asians [9]. Combined, these data may suggest that ovarian
function between Asians and Caucasians, indeed, differs but this
difference may not be expressed in IVF pregnancy rates until the
ovarian reserve is critically diminished at more advanced female
age.
Poor pregnancy rates in African women, in contrast, confirm
the literature [1,4,7,10]. Why African and Asian patients in this
study demonstrate such contradictory findings remains to be
determined.
As Table 1 demonstrates, only BMIs differed statistically
between groups. While on first glance this difference may appear
minor, adding age to the logistic regression marginalized the
statistical significance of FMR1 for pregnancy (P=0.06) but this
significance was fully restored by adding BMI to the regression.
BMI may, therefore, under certain circumstances be more
important than generally appreciated. The importance of BMI
may relate to PCO-like phenotypes: As noted het-norm/low is
closely associated with a slim PCO-like phenotype [32]. Signifi-
cantly higher BMI in Africans would suggest underrepresentation
of this phenotype.
It is important to note that the here investigated patient
population cannot be considered representative of the typical
infertility population seen at average fertility centers. Though
mean ages of infertile women reaching IVF are increasing in most
developed countries, our center’s patients have been exceeding
reported age increases, reaching a mean of 39.5 years by 2009.
Concomitantly, we witnessed between 2005 and 2009 a switch
from over 60% under age 40 to approximately the inverse. In
parallel, younger women demonstrated significantly declining
ovarian reserve, based on AMH levels (www.centerforhumanre-
prod.com), when already in 2006 diminished ovarian reserve was
recorded in over 50 percent of IVF patients [34].
Specific factors, responsible for unexpectedly good pregnancy
outcomes in Asians, can also not be ruled out. One may be
utilization of dehydroepiandrosterone (DHEA) supplementation,
which greatly improves infertility treatment success in women with
diminished ovarian reserve [35]. This beneficial effect, at least
theoretically, could disproportionally benefit Asians.
Here reported IVF pregnancy rates in Caucasians and Asians,
considering their poor ovarian reserve, are actually beyond
expectations, while those of Africans appear more in line with
expectations at mean ages of 38 years, FSH of 11.0 mIU/mL and
AMH of 1.4 ng/mL. Current treatment interventions with
diminished ovarian reserve may, therefore, indeed benefit
Caucasians and Asians disproportionally, a hypothesis currently
under investigation.
With FMR1 mapping to Xq27.3 [17], the long arm of the X
chromosome appears of increasing importance. For example, in
Turner syndrome Xq21 terminal deletions are common, often
large, and characterized by primary or secondary amenorrhea
[36,37]. POF/POI demonstrates a 4MB locus exactly at Xq27-
q28 [37]. In balanced translocations only Xq23-q27 deletions are
associated with POF/POI [37]. The long arm of the X
chromosome also contains multiple loci, promoting autoimmunity
[37] and, therefore, increasingly looks like a cross roads of ovarian
function and autoimmunity [26,32].
This study confirms that African women experience lower IVF
pregnancy rates than Caucasians and Asians. Risk towards lower
rates is independently associated with het-norm/low FMR1. The
association of FMR1 sub-genotypes and risk/protection for/from
autoimmunity suggests that autoimmunity may be associated with
lower pregnancy rates in IVF.
Research on the effects of race/ethnicity on reproductive
success has to continue, including race/ethnicity – bases
assessments of infertility outcomes. Indeed, the reporting of
universal treatment outcomes, independent of race/ethnicity,
appears counterproductive and, possibly, even misleading.
This study also reaffirms the rapidly evolving importance of
FMR1 in infertility. Initially believed to have only diagnostic
importance [29,30,21], it now increasingly also assumes prognostic
relevance in regards to treatment success [26].
Finally, autoimmunity in reproduction for decades has been
highly controversial [38]. Proximity of FMR1 and autoimmune
loci on the long arm of the X chromosome appears not
coincidental. Investigations of autoimmune effects in reproduction,
therefore, deserve another chance but, probably, require stratifi-
cation of patient populations based on ovarian function-related
FMR1 genotypes and sub-genotypes.
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